Pseudoprogression or unexpected favorable response to third-line therapy: a challenging metastatic bladder cancer case.

Porto Biomed J · 2020 · PMC7722396 · PMID 33299940

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

For patients with PD-L1 CPS score <10%, there was numerically greater OS with pembrolizumab, but it did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.